GB2465088B - miRNA expression in the characterisation and classification of cancer - Google Patents

miRNA expression in the characterisation and classification of cancer

Info

Publication number
GB2465088B
GB2465088B GB0920030.4A GB0920030A GB2465088B GB 2465088 B GB2465088 B GB 2465088B GB 0920030 A GB0920030 A GB 0920030A GB 2465088 B GB2465088 B GB 2465088B
Authority
GB
United Kingdom
Prior art keywords
characterisation
cancer
classification
mirna expression
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0920030.4A
Other versions
GB2465088A (en
GB2465088A8 (en
GB2465088A9 (en
GB2465088C (en
GB0920030D0 (en
Inventor
Michael Klass
Christine Kuslich
George Poste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caris Life Sciences Inc
Original Assignee
Caris MPI Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris MPI Inc filed Critical Caris MPI Inc
Priority claimed from PCT/US2009/062880 external-priority patent/WO2010062706A2/en
Publication of GB0920030D0 publication Critical patent/GB0920030D0/en
Publication of GB2465088A publication Critical patent/GB2465088A/en
Publication of GB2465088A9 publication Critical patent/GB2465088A9/en
Publication of GB2465088A8 publication Critical patent/GB2465088A8/en
Application granted granted Critical
Publication of GB2465088B publication Critical patent/GB2465088B/en
Publication of GB2465088C publication Critical patent/GB2465088C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB0920030.4A 2008-10-30 2009-10-30 miRNA expression in the characterisation and classification of cancer Expired - Fee Related GB2465088C (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US10974208P 2008-10-30 2008-10-30
US11257108P 2008-11-07 2008-11-07
US11404508P 2008-11-12 2008-11-12
US11405808P 2008-11-12 2008-11-12
US11406508P 2008-11-13 2008-11-13
US15118309P 2009-02-09 2009-02-09
US27804909P 2009-10-02 2009-10-02
US25045409P 2009-10-09 2009-10-09
US25302709P 2009-10-19 2009-10-19
PCT/US2009/062880 WO2010062706A2 (en) 2008-10-30 2009-10-30 Methods for assessing rna patterns

Publications (6)

Publication Number Publication Date
GB0920030D0 GB0920030D0 (en) 2009-12-30
GB2465088A GB2465088A (en) 2010-05-12
GB2465088A9 GB2465088A9 (en) 2010-06-30
GB2465088A8 GB2465088A8 (en) 2010-12-01
GB2465088B true GB2465088B (en) 2012-07-18
GB2465088C GB2465088C (en) 2016-01-27

Family

ID=41509440

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0920030.4A Expired - Fee Related GB2465088C (en) 2008-10-30 2009-10-30 miRNA expression in the characterisation and classification of cancer

Country Status (1)

Country Link
GB (1) GB2465088C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2906713A1 (en) * 2012-10-10 2015-08-19 The Institute of Cancer Research: Royal Cancer Hospital Micro-rna biomarkers for prostate cancer
CN103861121B (en) * 2012-12-10 2016-02-24 中国医学科学院基础医学研究所 The purposes of microRNA molecules miR491-5p in the treatment of cancer of pancreas and/or diagnosis and/or prognosis
EP2961327B1 (en) 2013-02-27 2018-07-11 Koninklijke Philips N.V. Optical guided vacuum assisted biopsy device

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152115A1 (en) * 1998-02-25 2004-08-05 Anziano Paul Q. Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
US20040152112A1 (en) * 2002-11-13 2004-08-05 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
WO2004070056A2 (en) * 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2006066965A2 (en) * 2004-12-24 2006-06-29 Stichting, Katholieke Universiteit, The Universitymedical Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer
WO2007081740A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008112283A2 (en) * 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
WO2009058893A2 (en) * 2007-10-29 2009-05-07 University Of Southern California Preventing hyaluronan-mediated tumorigenetic mechanisms using intronic rnas
WO2009108860A2 (en) * 2008-02-28 2009-09-03 The Ohio University Rasearch Foundation Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152115A1 (en) * 1998-02-25 2004-08-05 Anziano Paul Q. Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
US20040152112A1 (en) * 2002-11-13 2004-08-05 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
WO2004070056A2 (en) * 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2006066965A2 (en) * 2004-12-24 2006-06-29 Stichting, Katholieke Universiteit, The Universitymedical Mrna ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer
WO2007081740A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2008112283A2 (en) * 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
WO2009058893A2 (en) * 2007-10-29 2009-05-07 University Of Southern California Preventing hyaluronan-mediated tumorigenetic mechanisms using intronic rnas
WO2009108860A2 (en) * 2008-02-28 2009-09-03 The Ohio University Rasearch Foundation Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Cancer Gene Ther; Vol 16, pp 206-216 (2009). Tong et al.. "MicroRNA profile analysis of human prostate cancer" *
Cancer Res; Vol 69, pp 3356-3363 (2009). Sun et al. "The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines" *
Clin Oncol Cancer Res; Vol 6, pp 21-28 (2009). Li et al. "Expression of 6 MicroRNAs in prostate cancer and its significance" *
Eur Urol; Vol 54, pp 1081-1088 (2008). Haese et al. "Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy" *
J Urol; Vol 179, pp 1804-1810 (2008). Nakanishi et al. "PCA3 molecular urine assay correlates with prostate cancer tumour volume..." *
J Urol; Vol 181, pp 2508-2514 (2009). Ouyang et al. "A duplex quantitative polymerase chain reaction assay based on quantification...." *
Mol Cancer; Vol 8, pp 17 (2009). Siva et al. "Molecular assays for the detection of microRNAs in prostate cancer". Available online at: http://www.molecular-cancer.com/content/pdf/1476-4598-8-17.pdf *
The Prostate; Vol 67, pp 881-887 (2007). Martijn et al. "Molecular PCA3 diagnostics on prostatic fluid" *
The Prostate; Vol 68, pp 1215-1222 (2008). Martijn et al. "Detailed analysis of histopathological parameters in radical prostatectomy specimens..." *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer

Also Published As

Publication number Publication date
GB2465088A (en) 2010-05-12
GB2465088A8 (en) 2010-12-01
GB2465088A9 (en) 2010-06-30
GB2465088C (en) 2016-01-27
GB0920030D0 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EP2379443A4 (en) Nanostructured articles and methods of making nanostructured articles
PL2451279T3 (en) Benzosulfonamide derivatives, compositions thereof, and their use in preventing metastasis of cancer cells
EP2401405A4 (en) Micrornas in never-smokers and related materials and methods
TWI559930B (en) Anti-tnf-α antibodies and their uses
IL210804A (en) Benzylidenehydrazides and uses thereof
EP2209625A4 (en) Articles and methods of making the same
EP2277049A4 (en) Autoantibodies in the detection and treatment of cancer
PL2278952T3 (en) Skin and hand cleansers
EP2268673A4 (en) Polypeptide-polymer conjugates and methods of use thereof
GB0914644D0 (en) Novel agents and uses thereof
HK1170485A1 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer 124--3-
EP2307518A4 (en) Fixed abrasive particles and articles made therefrom
EP2225364A4 (en) Cancer classification and methods of use
EP2516429A4 (en) Paxillin stimulating compositions and cosmetic uses thereof
GB0819883D0 (en) Product and uses
EP2291377A4 (en) Imidazopyrimidinones and uses thereof
HK1161720A1 (en) Dihydroetorphines and their preparation
EP2418947A4 (en) Bleached dextrin and methods of forming the same
EP2286774A4 (en) Wearing article and method of folding the same
EP2247601A4 (en) Thiazopyrimidinones and uses thereof
GB2465088B (en) miRNA expression in the characterisation and classification of cancer
GB2473297B (en) Hair extension and hair extension process
GB0912744D0 (en) Methods and uses
EP2345404A4 (en) Pencil-shaped cosmetic and cosmetic product
GB0807073D0 (en) Methods and manufacture of extended area articles

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20130215 AND 20130220

S117 Correction of errors in patents and applications (sect. 117/patents act 1977)

Free format text: REQUEST FILED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 14 AUGUST 2014

S117 Correction of errors in patents and applications (sect. 117/patents act 1977)

Free format text: CORRECTIONS ALLOWED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 14 AUGUST 2014, ALLOWED ON 20 JANUARY 2016

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20161030